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Background: Malaria is a major global cause of deaths and a vaccine is urgently needed.
Results: We have employed the P. falciparum merozoite antigens MSP2-3D7/FC27 and AMA1, used them in ELISA,
and coupled them in different ways using surface plasmon resonance (SPR) and estimated affinity (measured as kd)
of monoclonal as well as naturally-acquired polyclonal antibodies in human plasma. There were major differences in
kd depending on how the antigens were immobilized and where the His-tag was placed. For AMA1 we could see
correlations with invasion inhibition. Using different immobilizations of proteins in SPR, we could see only moderate
correlations with levels of antibodies in ELISA, indicating that in ELISA the proteins were not uniformly bound and
that antibodies with many specificities exist in natural immunisation. The correlations between ELISA and SPR were
enhanced when only parasite positive samples were included, which may indicate that high affinity antibodies are
difficult to maintain over long periods of time. We found higher kd values for MSP2 (indicating lower affinity) compared
to AMA1, which might be partly explained by MSP2 being an intrinsically disordered protein, while AMA1 is globular.
Conclusions: For future vaccine studies and for understanding immunity, it is important to consider how to present
proteins to the immune system to achieve highest antibody affinities.
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Malaria is a disease that kills up to one million people
every year [1]. Immunity against the life-threatening infec-
tion caused by Plasmodium falciparum develops slowly
and only after repeated exposure [2]. Humoral immunity,
besides cell-mediated immunity, is important in protec-
tion against the disease [3], and it has been shown that
antibodies from immune individuals can reduce parasit-
emia and clear clinical symptoms [4]. Some of the anti-
bodies are directed against merozoite antigens of the
parasite, like Merozoite Surface Protein 2 (MSP2) and Ap-
ical Membrane Antigen 1 (AMA1) [5–10]. These antigens* Correspondence: kristina.persson@ki.se
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creativecommons.org/publicdomain/zero/1.0/have both been considered promising vaccine candidates,
but so far no vaccine has been shown to be highly effica-
cious in phase 2 trials [11]. A better understanding of the
presentation and form of antigens in vaccines, and the af-
finity and function of antibodies to these antigens is essen-
tial to advance the development of effective vaccines.
MSP2 is a 25–30 kDa merozoite membrane protein
[12–14], which has a central variable region flanked by con-
served N- and C-terminal regions (Fig. 1). MSP2 appears to
play an important role in erythrocyte invasion, and is rap-
idly processed immediately post-invasion [15]. Recombin-
ant MSP2 is an intrinsically disordered protein. However,
the parasite antigen appears more ordered, which may be
due to interactions with the merozoite membrane or
oligomerization of MSP2 [16]. MSP2 parasite alleles can be
categorized into two major groups, 3D7 and FC27 [6, 17].ticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Schematic drawing showing the different mAb binding sites on the MSP2-FC27 and MSP2-3D7 proteins
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acquired and vaccine-induced antibodies that appear to be
protective, and that the response is strain-specific [18–20].
A phase 2 trial of a MSP2-containing vaccine demonstrated
some protective efficacy [19]. Antibodies raised against
MSP2 generally do not directly inhibit invasion [15] but
have a growth inhibitory effect in antibody-dependent cellu-
lar inhibition (ADCI) assays [14, 21–23].
AMA1 is an 82-kDa type 1 integral membrane protein
that is expressed both at the sporozoite- and merozoite
stages. Native as well as recombinant forms of the antigen
have been shown to induce various levels of protection
against challenge from Plasmodium parasites in simian
[24, 25] and rodent models [26–28]. In humans, presence
of naturally-acquired antibodies against AMA1 has been
associated with protection from disease [29–33], and
monoclonal antibodies have been shown to inhibit inva-
sion of erythrocytes [34–37]. A recent phase 2 trial
demonstrated protective effect against malaria due to
vaccine-like alleles during the first season after vaccin-
ation, but the effect was lost after the second season [38].
Measurement of the affinity or 'functional affinity' [39]
of an antibody for its antigen has been shown to be a
prominent determinant of the biological efficacy of an
antibody [40, 41]. For pathogens such as bacteria, affinity
of antibodies has been proven to be of importance for pro-
tection from disease after vaccination [42–44]. However,
there is limited knowledge of antibody affinity to malaria
parasite antigens, how this is influenced by protein struc-
ture, how it differs between antigens, and how the presen-
tation of an antigen influences affinity. Moreover, there
are limited data defining optimum methods to measure
affinity, and the affinity of antibodies directed against un-
structured proteins (such as MSP2) in particular. Recently,
our group showed that naturally-acquired high affinity
antibodies to MSP2-3D7, measured by SPR, were associ-
ated with protection against malaria [45].
In this study, we have focussed on conformational
changes of the intrinsically disordered MSP2 protein,and studied how these changes result in different bind-
ing affinities of naturally-acquired as well as mAb. For
comparison, we have also used AMA1, which is a pro-
tein with a globular fold and a more stable structure.
Different ways of binding a protein to a surface can result
in different conformations of the protein, rendering differ-
ent epitopes accessible to binding of antibodies; this may
be especially important for an intrinsically disordered pro-
tein like MSP2, We used MSP2 proteins with the His-tag
bound to different ends of the proteins for immobilization,
to further evaluate antibody binding. These studies are im-
portant for optimal selection of vaccine candidates, and
for choosing how they should be presented to the immune
system, since high affinity antibodies are probably one of
the criteria for creating long-term immunity.
Results
Estimation of affinity of human antibodies using
dissociation rates (kd)
For estimation of affinity of antibodies in human plasma,
we measured dissociation rates, kd, of antibodies in patient
plasma. Recombinant antigens were bound using amine N-
or C-terminal coupling to CM5 sensor chips, or His-tagged
coupling to NTA chips. Plasma was flowed over the chips.
One lane was used as reference lane (no antigen present).
Swedish non-immune plasma was used to determine the
cut-off to be considered as background level. Dissociation
rates were independent of plasma concentrations. At least
two different plasma concentrations were used to confirm
the same values of kd irrespective of concentration. To test
the stability of the bound recombinant proteins, a pool of
plasma (immune individuals) was used after every 20 sam-
ples. The kd values were independent of the loss of protein
over time (seen as a decrease in response units). Anti-IgG
was added directly after the plasma samples for a subset of
ten samples, to confirm the presence of bound IgG to the
recombinant proteins (Additional file 1: Figure S1).
To avoid loosing antibodies that might exist only in
low concentrations, and to include antibodies of all
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Fig. 3 Comparison of affinity responses (measured as kd) between
amine N- and C- terminal coupling. PNG and Ugandan samples
(n = 170) were used together with recombinant MSP2-FC27, MSP2-3D7
and AMA1. The box plot values represent the 25th percentile, median,
and the 75th percentile. The whisker range determines the 5th and
95th percentiles
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antibodies. We evaluated the procedure using mixtures
of plasma containing antibodies with different affinities.
Ten different PNG plasma samples were analyzed with
MSP2-FC27 bound through amine N-terminal coupling.
Individual kd ranged from 3.3x10
−5-7.8x10−4 s−1 (Fig. 2).
The theoretically calculated mean for these samples was
2.9x10−4 s−1, but when an equal mixture of all ten sam-
ples together was measured, the experimental kd was
1.6x10−4 s−1, indicating a tendency for the mixtures to
show a slightly higher affinity than the calculated theor-
etical one. This was also the case for a combination of
mAb; the individual kd for mAb 1 F7 and 2 F2 were
6.8x10−5 and 1.1x10−3 respectively, whereas the experi-
mental kd for a 50:50-mixture was 4.7x10
−4 s−1.
Different affinities of human antibodies for different proteins
When plasma from individuals in PNG/Uganda (n =
170) were examined using N-terminal amine coupling of
antigens, antibodies against AMA1 had the highest affin-
ity, followed by anti-MSP2-3D7 and anti-MSP2-FC27
antibodies (Fig. 3, all p-values < 0.001). Examples of ori-
ginal SPR data is shown in Additional file 1: Figure S2.
The results were the same whether PNG or Uganda was
analyzed separately, or if all were together (p < 0.0001
for all differences). The same pattern (highest affinity for
antibodies against AMA1) was seen for all ages. To es-
tablish that the effects of plasma binding to recombinant
proteins on the SPR chip was due to antibodies, IgG was
purified from 5 of the PNG samples and tested against
MSP2-3D7 +MSP2-FC27. There were no significant dif-
ferences in kd between the purified IgG samples and the
corresponding plasma (Additional file 1: Figure S3), indi-
cating that the majority of the effect measured was due
to IgG antibodies present in plasma.PN
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Fig. 2 Affinity of antibodies (measured as kd) in plasma from
individuals living in PNG. MSP2-FC27 was bound to the chip through
amine N-terminal coupling. Ten different plasma samples were
analyzed separately as well as in a mixture (PNG pool). The pooled
sample shows an inclination towards higher affinity, when compared
with the theoretically calculated mean (Th. mean) for the same
sample mixtureThe samples from PNG were from asymptomatic indi-
viduals. We compared parasite positive and parasite
negative individuals, and found that there were no differ-
ences in age or affinity between parasite positive and
negative individuals, however the number of samples in
the parasite positive group was limited.
Affinity of human antibodies using N-or C-terminal amine
coupling of antigens to the chip
After observing variable affinity responses for antibodies
against MSP2 and AMA1 proteins, we investigated whether
the coupling chemistry and/or orientation of the proteins
affected the kd values. Along with using the more common
method of N-terminal amine coupling, the recombinant
proteins were immobilized onto CM5 chips through a
C-terminal amine coupling. Higher kd values for anti-
bodies from Ugandan and PNG samples were observed
when C-terminal amine coupling of MSP2-3D7 and
AMA1 proteins were used, compared to N-terminal coup-
ling above, whereas the opposite was seen for MSP2-FC27
(Fig. 3). The overall (p < 0.0001) and individual differ-
ences in responses between N- and C- terminal cou-
plings were significant (MSP2-FC27/MSP23D7/AMA1;
n = 170; p = <0.0001/0.03/0.0001, respectively). When
the Ugandan and PNG samples were analyzed separately
the results showed similar patterns (PNG; MSP2-FC27/
Reddy et al. BMC Microbiology  (2015) 15:133 Page 4 of 11MSP23D7/AMA1; p = 0.003/0.02/<0.0001, respectively;
Uganda: MSP2-FC27/MSP23D7/AMA1; p = <0.0001/
0.1/0.0002, respectively).
For the PNG samples, there were no differences in the
affinities of antibodies to any of the proteins between
parasite positive or negative (not shown).
Affinity of human antibodies using N- or C-terminally
His-tagged coupling of antigens
MSP2-FC27 and MSP2-3D7 were bound to Ni-NTA
chips through either N- or C-terminal His-tags. Five dif-
ferent PNG samples were used and flowed over the
chips in the same way as for the amine coupling (Fig. 4).
We used four different ways of binding MSP2-FC27
(amine N-terminal, amine C-terminal, or through the
His-tag at either the N-or C-terminal end), and the only
significant difference for binding of the five PNG sam-
ples was between amine N- and C-terminal couplings
(p = 0.045), with lower affinity for N-terminal coupling.
For MSP2-3D7, the different methods of coupling re-
sulted in highly significant differences in antibody-
binding affinities (p < 0.0001 for all comparisons, except
between N- and C-terminal His-tagged couplings where
no difference could be seen). The five samples were from
individuals aged 5–9 years, but no obvious trends could
be seen with increasing ages (not shown). The mostN-
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Fig. 4 Comparison of affinity response (measured as kd) of five PNG
plasma samples. Different bindings to the chip for MSP2-3D7 or
MSP2-FC27. N-terminal coupling exploits amine groups in the ligand,
C-terminal coupling exploits carboxyl groups. Hexa His–N terminal
protein coupling uses the capture of His-tagged constructs at the
N-terminal end of the protein, and hexa His-C-terminal protein
coupling uses the capture of His-tagged constructs at the C-terminal
end of the protein. The box plot values represent the 25th percentile,
median, and the 75th percentile. The whisker range determines the
5th and 95th percentilesstriking finding for the different couplings was the low
affinity of antibodies to the His-tagged 3D7 proteins,
whether coupled through their N- or C-terminal His-tag.
Affinity of mAb
The effect of different coupling procedures on the kd
values of anti-MSP2 mAb was examined, with MSP2-
FC27/MSP23D7 bound using N- or C-terminal amine
coupling and N- or C-terminal His-tag coupling (Fig. 5a, b).
Examples of original SPR data is shown in Additional file 1:
Figure S2. For MSP2-FC27, a pattern could be discerned
between binding of antibodies to different parts of the
protein. 9G8 and 4D11, which bind to the conserved
C-terminal part of MSP2, generally bound with quite
high affinities, but with slightly higher affinities to the
His-tagged proteins compared to the amine coupled
proteins, and in both cases with similar affinities be-
tween N- and C-terminal bindings. 6C9, 1 F7 and 9H4
also bind to the conserved C-terminal part of MSP2,
but binding is dependent on an intact disulphide bond,
and we could see higher affinities when binding to the
N-terminally coupled proteins. 6D8 and 8G10, which
bind towards the N-terminal end of MSP2, showed similar,
high affinities when using His-tagged coupling but slightly
higher affinities when using amine N-terminal coupling
compared to amine C-terminal coupling.
For MSP2-3D7, the pattern between different binding
sites of the antibodies was less clear. 9G8 and 4D11
(which bind to the conserved C-terminal part of MSP2)
bound with lower affinity to the N-terminally amine
coupled protein compared to the rest of the proteins.
1 F7 and 9H4 (which also bind to the conserved
C-terminal part of MSP2) bound with very high affinity
to the N-terminally amine coupled protein, but with
lower affinity to the rest of the proteins. 6C9, which is
supposed to bind in a similar way as 1 F7 and 9H4, was
found to bind with lower affinity for the N-terminally
amine coupled protein compared to 1 F7 and 9H4. The
mAb 6D8, which recognizes a conserved N-terminal
epitope, bound with high affinity whatever way the
MSP2-3D7 protein was coupled to the chip. In general,
the antibodies that recognized the variable region of
MSP2-3D7 (11E1, 2 F2, 9D11) bound with the highest
affinity to the protein when using the amine C-terminal
coupling.
There was no cross reactivity observed between allele-
specific mAb (not shown).
As a comparison to the above MSP2 proteins, we also
tested the monoclonal antibody 1 F9, which bound very
strongly to AMA1 (coupled through N-termial coupling
to the chip). The kd results were in the 10
−6 range, but
as the off-rate was almost like a straight line due to the
very strong binding, it was difficult to estimate a true kd
value (not shown).
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Fig. 5 Affinity responses measured as kd values of the mAb against MSP2 using different couplings. The MSP2 proteins (A) MSP2-FC27 (B) MSP2-3D7
were coupled in four different ways to the chip; either through amine or His-tagged N-terminal or C-terminal coupling. The location of mAb binding
to MSP2 is shown in Fig. 1
Fig. 6 Correlation for PNG samples between ELISA and SPR results
for amine N-terminal coupling of AMA1. Parasite positive samples
indicated with squares, R2 = 0,65 p = 0.0005; parasite negative samples
indicated with triangles, R2 = 0,57 p < 0.0001; all samples included
R2 = 0.54 p < 0.0001)
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All individuals had antibodies in ELISA to the three re-
combinant antigens studied, but there was no associ-
ation with age (whether analyzed separately for Uganda/
PNG samples or together). For PNG samples there was
no difference in antibody levels between parasite positive
and negative individuals.
When the antibody levels in ELISA were compared to
SPR, correlations were seen for the Ugandan samples
(where all had malaria) mainly for AMA1 (ELISA-N-ter-
minal amine coupling R2 = 0.25, p < 0.0001, ELISA-C-
terminal amine coupling R2 = 0.41, p < 0.0001).
For the PNG samples, there were correlations for
AMA1 both when parasite positive and negative samples
were included for N-terminal coupling (Fig. 6). For
ELISA-C-terminal amine coupling R2 = 0.10, p = 0.007
for all samples, R2 = 0.54, p = 0.003 only parasite positive
and non-significant R2 = 0.02 only parasite negative.
Weaker correlations were seen in the PNG samples be-
tween ELISA-SPR for MSP2; MSP2-3D7 ELISA-N-terminal
amine coupling R2 = 0.08, p = 0.02 all samples, R2 = 0.31,
p = 0.04 only parasite positive. ELISA-C-terminal coupling
R2 = 0.06, p = 0.04 all samples, R2 = 0.34, p = 0.03 only para-
site positive. When MSP2-FC27 was used in N-terminal
amine coupling, the only correlation with ELISA was for
parasite positive (R2 = 0.31, p = 0.04).In conclusion, the analysis showed better correlations
between ELISA and SPR results for AMA1 compared to
the MSP2 proteins, and better correlations when only
parasite positive samples were included in the analysis.
Invasion Inhibition and correlations with ELISA and SPR
For the Ugandan samples, invasion inhibitory experi-
ments were performed using two clinical isolates (UAS31,
UAM37). We could see correlations between invasion
Reddy et al. BMC Microbiology  (2015) 15:133 Page 6 of 11inhibition and SPR results for UAM37 and amine N-terminal
SPR results for MSP2-3D7 (R2 = 0.14, p = 0.03), and for
both clinical isolates and amine C-terminal SPR for
AMA1 (R2 = 0.11, p = 0.01 for UAM37 and R2 = 0.08,
p = 0.04 for UAS31). For non-significant correlations, R2
were <0.03. Invasion inhibition results were also compared
to ELISA, and significant correlations were seen for
UAS31 versus AMA1 (R2 = 0.24, p = 0.0002), UAS31-
MSP2-FC27 R2 = 0.21, p = 0.0005, and for UAM37 versus
AMA1 (R2 = 0.21, p = 0.0006). For the non-significant cor-
relations, R2 values ranges were <0.10.
Discussion
For most merozoite surface proteins, the conformation
of the native protein located on the surface of the mero-
zoite is not known. A number of proteins, including
AMA1, have globular domains stabilized by intramo-
lecular disulphide bonds [26, 29]. Such structures will be
relatively stable but protein-protein interactions can re-
sult in significant changes in conformation as has been
described for AMA1 when it interacts with RON2 [46].
For MSP2, an intrinsically disordered protein, protein-
protein interactions, or interactions with the membrane
itself, might have major effects on the conformation of
the protein and thereby affect the interaction between
MSP2 and antibodies. Both AMA1 and MSP2 are known
targets of naturally-acquired protective immune re-
sponses, as a majority of adults living in malaria endemic
regions have high levels of antibodies as measured by
ELISA [29, 47, 48]. However, in vaccine studies, it is im-
portant to choose proteins that can generate functionally
important antibodies. An antibody that is going to func-
tion in vivo probably needs to be of high affinity, includ-
ing a low off-rate, so that once an antibody is bound to
the merozoite surface, it can stay there during the inva-
sion process. It has been shown before that it is of im-
portance with both antibody titer and affinity of the
antibodies [49, 50]. We tested the monoclonal antibody
1 F9, directed against AMA1, and found an extremely kd
value, indicating a very strong binding. This is in line
with earlier studies of 1 F9, which have shown that 1 F9
and AMA1 interacts with a very large interface, creating
an environment suitable for a stable structure [51]. In
future studies, it would be of interest to include other
merozoite proteins, such as MSP1, which is also a vac-
cine candidate, for testing in SPR to investigate whether
this protein can also induce high affinity antibodies. The
part of MSP1 that is inserted into the erythrocyte con-
sists of two epidermal growth factor-like domains, which
(like AMA1) are very stable in their structure due to
several disulphide bonds.
Our findings demonstrate that there are major differ-
ences in antibody affinity (measured as kd) for two lead-
ing merozoite vaccine candidates, which may reflectstructural differences. We show that the form in which an-
tigens are immobilized significantly influences antibody af-
finity, which is relevant for understanding how to present
antigens in vaccines, and how to measure antibody affinity
in vaccine trials and studies of naturally-acquired immun-
ity. Antibody affinity also generally increased with increas-
ing antibody levels, consistent with increasing malaria
exposure leading ultimately to protective immunity, in-
cluding both higher affinity of antibodies as well as higher
levels of antibodies. It should be noted that kd values are
independent of concentration, which is convenient in this
case. In general, measuring antibodies by ELISA cannot be
relied on as a good correlate of antibody affinity. It has
been shown before when using Guanidine Thiocyanate,
that high levels of antibodies against MSP2 is not neces-
sarily related to avidity of the antibodies [52]. Duration of
antibodies is also important, MSP2 antibodies have been
shown to be of shorter half-life than antibodies against
AMA1 [53]. In this case it was probably not because of
different antibody subclasses, but in other cases this might
be a more important reason for differences in half-lives of
antibodies as has been shown for EBA175 [54].
In our studies, we measured kd values of naturally-
acquired, human antibodies. We believe that our method
is more physiological and more precise than many other
methods since we include all antibodies (without purifi-
cation) in our measurements and the net effect is mea-
sured. SPR is also a method where the measurements
are performed under flow, which is the natural situation
in vivo. Using this method, we could see higher affinity
of naturally-acquired antibodies to AMA1 compared to
MSP2, and higher affinity for the 3D7 allele of MSP2
compared to FC27. This pattern was consistent whether
measured in samples from Uganda or PNG, and for both
symptomatic and asymptomatic individuals. The higher
affinity for AMA1 could be due to a more stable struc-
ture of the protein, making it easier for antibodies to
stay bound to their target, compared to MSP2 that has a
more flexible structure. For MSP2, strain-specificity has
been noted before to be of importance for formation of
a protective response [19]. It might be that the 3D7 al-
lele has been more common in the studied populations
over the years than FC27; 3D7 is generally more preva-
lent globally, and is more prevalent in the PNG study
population26, suggesting that greater exposure may
partly explain the greater affinity of antibodies to MSP2-
3D7. Also in the Ugandan population, MSP2-3D7 has
been shown to be more common with 96 % of patients
with uncomplicated malaria being positive, and 74 % be-
ing positive for MSP2-FC27 [55]. However, there could
also be intrinsic differences in the tendency to form a
stable structure between the allelic forms of the proteins.
Both forms have central repeat regions that are probably
important for formation of antibodies, since many of the
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not so much against the N- or C- terminal conserved
parts [56–59]. However, this central region is different
for the two proteins and when we coupled the proteins
to the SPR-chips, it was quite clear that there were dif-
ferences in affinity depending on the way the proteins
were bound. For 3D7, the affinity of naturally-acquired
antibodies was higher when the protein was bound
through its N-terminal part, while for FC27 the affinity
was higher when bound through its C-terminal part.
These results could be explained by antibodies being di-
rected against epitopes that are central, but still more
close to the C-terminal region for MSP2-3D7, and more
close to the N-terminal region in MSP2-Fc27 (where the
variable regions are positioned).
When the results from SPR were compared to anti-
body levels measured by ELISA, there were correlations
both with results from amine N-terminal and C-terminal
coupling, indicating that epitopes at both ends of the
protein are available in ELISA. Correlations were often
weak, emphasizing that SPR and ELISA are two different
methods that measure different things, and correlations
might therefore not be consistently present. We also
compared SPR results to invasion inhibition assays, and
saw very modest correlations. When ELISA was com-
pared to invasion inhibition results, there were stronger
correlations between levels of AMA1 and invasion in-
hibition compared to levels of MSP2, supporting earlier
results that have suggested AMA1 antibodies to be dir-
ectly inhibitory, while MSP2 antibodies might need
ADCI to be inhibitory.
For most of the MSP2 mAb, there were clear differ-
ences in affinity of bound antibodies depending on
which coupling method was used for the proteins. We
can’t be sure that what we call “N”-and “C”-terminal
coupling is really using those ends of the proteins, but at
least we know that it is totally different ways of binding
the proteins. The proteins probably form different struc-
tures when bound differently, since we know that the
mAb are homogenous. It has been shown before that al-
terations in kd values can be caused by conformational
changes in immobilized proteins when SPR has been ap-
plied [60–63]. Because this kind of difference was seen
both for mAb and for naturally acquired human poly-
clonal antibodies, we think it is not just an effect of in-
cluding different antibodies in the polyclonal response,
but that antibodies will bind with different affinities de-
pending on how the protein is presented to the antibody.
This is important knowledge, since an efficient vaccine
should probably be one that induces high affinity anti-
bodies and one has to consider in what way the proteins
are presented to the immune system.
For a small number of samples we tried coupling of
the MSP2 proteins through their His-tag. Binding ofnaturally acquired antibodies to MSP2-3D7 gave lower
affinity when bound through the His-tag, whether the
His-tag was at the N- or C-terminal end (Fig. 4). This
might be because the protein itself became more flexible
in structure when bound through the His-tag compared
to binding with amine coupling, making it more difficult
for antibodies to bind. It has been shown before that dif-
ferent environments can affect the structure of MSP2,
and it has even been suggested that the N-terminal part
of MSP2 can be stabilized by lipid interactions [16].
When mAb were used, the antibodies directed against
the conserved C-terminal part of MSP2 also showed a
lower affinity towards the His-tag coupled proteins.
Since this pattern was only seen when mAb against the
conserved C-terminal part of the protein were used, one
can speculate that many of the antibodies in plasma
were also directed against this part, at least for MSP2-
3D7. These results point out the potential importance of
the exact placement of added tags for creating a more
stable structure in proteins, especially when using intrin-
sically disordered proteins, in forming binding sites for
functionally important antibodies. In most SPR studies,
N-terminal coupling of proteins is used, since this is the
easiest to perform. C-terminal coupling includes an
extra step of serial dilutions of PDEA, and when His-
tags are used to bind proteins to the chips, every regen-
eration induces total loss of the bound protein from the
chips, which makes the experiments much more cum-
bersome to perform. However, one should be aware of
possible differences in results that can be induced
through different forms of binding of proteins, when
using SPR. The structure of MSP2 in the merozoite is
not known, and part of the reason for that is probably
that it is an unstructured protein, which makes it more
challenging to study compared to a protein with a more
stable structure, but placing His-tags at different ends
might help in facilitating for some specific antibodies
to bind. However, further studies are needed to clarify
the exact structure of MSP2 on the surface of the mer-
ozoite, and when this is known it should be easier to
decide which antibodies are best in protecting patients
from malaria.
Conclusions
In conclusion, we have measured affinity of both mono-
clonal and naturally-acquired antibodies in human plasma,
and we showed that the measurement of affinity was
dependent on how the proteins were bound to surfaces
and presented, and in which way the tag was bound to the
protein. This information is crucial for vaccine studies,
where the goal is to have the best possible conformation
of a protein and expose important epitopes to create anti-
bodies that are of high affinity and that can be functional
over a long period of time.
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Plasma samples
Plasma samples were collected from residents of Madang
Province, Papua New Guinea (PNG). The samples were
from a cross-sectional bleed in 2007 from individuals 1–52
years, of which 22 % were from parasite positive individuals
(determined by microscopy). This population experi-
ences year-round transmission of Plasmodium falcip-
arum malaria with seasonal variation. 100 PNG samples
were screened for IgG to MSP2 by ELISA. Positive sam-
ples (n = 74) were used. The Ugandan samples (n = 96)
were collected in a cohort study [64] from children
6 months - five years of age (mean age 20 months) with
malaria. The area of Apac has one of the world’s highest
transmission rates of malaria: EIR 1500/year.
Proteins and monoclonal antibodies
Recombinant MSP2-FC27/MSP2-3D7 proteins with hexa-
His tags either at N- or C-termini and AMA1-D10 were
expressed in E. coli and purified as described [12, 65]. The
MSP2 proteins that were used for amine coupling in SPR
analysis had the His-tag at the N-terminal end. SDS-
PAGE confirmed recombinant proteins to be monomers
(not shown). The mAb against MSP2 were produced in
mice [14]. 6D8 is directed against the conserved N-
terminal region of MSP2 3D7/FC27. 11E1, 9D11, 2 F2 are
directed against the MSP2-3D7 variable region, 8G10
against the MSP2-FC27 variable region. 1 F7, 6C9, 9H4,
4D11 and 9G8 are directed against the conserved C-
terminal regions in MSP2 3D7/FC27. All mAbs were di-
luted in HBS-EP running buffer.
Coupling of recombinant proteins to SPR chips
The different protein antigens were immobilized onto the
sensor chip surface as described in the manufacturers’
protocol for Biacore. For N-terminal coupling, a CM5 sen-
sor chip was used together with an N- terminal amine
coupling kit from Biacore, using EDC/NHS chemistry
[66]. The carboxymethylated dextran surface of the chip
was activated using an injection pulse (10 min, 5 μL/min)
containing a mixture of 0.05 M NHS and 0.05 M EDC.
The protein immobilization was accomplished by injecting
the protein solution at 100 μg mL−1 in coating buffer
(0.01 M sodium acetate buffer, pH 4.0) until the desired
response units were achieved. The remaining sites on the
sensor surface were blocked by injecting 1 M ethanol-
amine (pH 8.5) for 10 minutes. All steps were carried out
in a continuous flow of HBS-EP running buffer at 5 μL/
min, and all buffers were degassed prior to use.
The C- terminal coupling of proteins was achieved by serial
dilutions of PDEA in 0.1 M 2-morpholinoethanesulphonic
acid (MES), pH 5.0 (final concentration 4.0 mM - 0.5 mM)
and a constant concentration of protein (4.0 μg/mL) and
EDC (0.02 M), resulting in an introduction of reactivedisulfide groups on carboxyl residues in the protein. The
mixture was allowed to react for 1 hour on ice. The fol-
lowing was injected into the SPR machine in sequence;
30 μL NHS/EDC mixture; 20 μL 40 mM cystamine dihy-
drochloride in 0.1 M borate buffer pH 8.5; and 20 μL
0.1 M dithioerythritol (DTE) in 0.1 M borate buffer
pH 8.5. Finally, the protein was bound by injecting the
protein-PDEA mixture. Starting with the tube having the
least PDEA, the protein solution was injected until desir-
able response units were achieved. To block the unbound
sites, 20 μL 20 mM PDEA in 0.1 M formate buffer pH 4.3
containing 1 M NaCl, was injected.
Immobilization of histidine-tagged MSP2-FC27 and
MSP2-3D7 proteins (N- or C- terminal) through the His-
tag to a sensor chip NTA was achieved using the manufac-
turer’s protocol [67]. First, the sensor chip was loaded with
Ni2+ using a one minute pulse of 500 μM NiCl2 in modi-
fied running buffer (10 mM HEPES, 150 mM NaCl, 50 μM
EDTA. 0.005 % Surfactant P20, pH 7.4), followed by an in-
jection with the His-tagged protein (200 nM). Finally, a
one minute pulse of NiCl2 (500 μM) was injected to satur-
ate any remaining NTA sites with Ni2+ ions (40 – 50 RU),
and further increase in NiCl2 concentration had no ef-
fect on the immobilization level. After analyzing the
binding interactions with respective ligands, the chip
was treated with a three minute pulse of regeneration
solution (10 mM HEPES, 150 mM NaCl, 350 mM
EDTA, 0.005 % Surfactant P20, pH 8.3), which stripped
all the His-tagged proteins and Nickel off the chip,
demonstrated by the lack of binding after injection with
the same His-tagged proteins.
In conclusion, N-and C-terminal binding of proteins
means covalent binding of proteins to the sensor chip
surface, while when the His-tag is used for binding,
the binding is achieved through the Nickel-His binding.
N-terminal binding uses amine coupling, and since there
is an easily accessible amine group at the N-terminal
end of all proteins, this end of the protein will be bound
to the chip. However, also other amine groups in the pro-
tein could potentially bind to the chip, depending on how
accessible the amine groups are. The same reasoning can
be applied to C-terminal coupling. Even if we can not be
100 % sure that what we call N-and C-terminal coupling
is always really N-and C-terminal coupling, at least we
can be sure that the couplings are different, and we think
that quite often the bindings are actually through the ends
of the proteins. When the His-tag is used to couple the
protein, there are no other options for the protein but to
use the His-tag to bind to the chip.
Binding assays and analysis
The SPR binding assays were performed with a constant
flow rate of 30 μl min−1 at 25 °C. Plasma samples and
purified monoclonal antibodies (in different dilutions,
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bound recombinant proteins in HBS-EP buffer, pH 7.4.
At all dilutions, the association of antibodies with the
immobilized MSP2-FC27, MSP2-3D7 and AMA1 proteins
was monitored for 3 minutes followed by 10 minutes of
dissociation. Residual bound antibody was removed by
washing the chip with 10 mM glycine-HCl (pH 1.5) for
5 seconds at 5 μL/min. Reequilibration between the sensor
surfaces and running buffer was established prior to injec-
tion of the next sample. Response was monitored as a
function of time at 25 °C. Kinetic parameters were evalu-
ated by using the BIAevaluation 4.1 software.ELISA
ELISA plates (Maxisorb; NUNC 44-2404-21; Denmark)
were coated overnight with 200 ng per well of purified
recombinant proteins (MSP2-FC27, MSP2-3D7 or
AMA1) in PBS, blocked with PBS–5 % skimmed milk
powder, and used for standard ELISA [33]. After wash-
ing 3x with 0.1 % Tween/PBS, plasma samples were
added in different dilutions. After another washing step,
rabbit anti-human IgG conjugated to alkaline phosphat-
ase (Sigma, A9544) was applied as a detection antibody.
Finally, p-nitrophenyl phosphate tablets (Sigma, N2765)
was used as a substrate. Color development was mea-
sured as the OD at 405 nm. All ELISAs were done in
triplicates.Invasion Inhibition Assay
The method to study invasion inhibitory antibodies has
been described previously [68]. Two Ugandan P. falciparum
isolates [64], UAM37 (from a patient with mild malaria,
containing both FC27 and 3D7 alleles of MSP2), and
UAS31 (from a patients with severe malaria, containing
the 3D7 allele of MSP2) were cultured in vitro (for a
couple of months after collection from the patients) in AB
+ non-immune Swedish serum and gassed with 90 %
NO2, 5 % O2 and 5 % CO2 and placed in a shaker incuba-
tor. In brief, parasites were synchronized (5 % sorbitol,
v/w) before assay start, and at the day of the assay the ma-
jority of the parasites were at late-pigmented trophozoite
stage. 50 μl of parasite suspensions were cultured for one
cycle in 96 well plates. 5 μl of dialyzed test plasma was
added to each well and all samples were run in duplicate.
Plates were incubated in a sealed, humidified, gassed box
and put in an incubator for 48 hours at 37 °C. Parasitemia
was estimated using hydroethidine (10 ug/ml; Sigma
Aldrich) in a flow cytometer (FACS Scan; BD) after ap-
proximately 48 hours (determined by the parasite stage).
Parasite invasion for each sample was measured in com-
parison to controls (invasion in presence of dialyzed non-
immune plasma).Statistics
Data analyses were performed using GraphPad Prisma
Version 5.0a software. To test for individual differences in
affinity to the recombinant antigens, Mann–Whitney test
was used. The Pearson correlation coefficient was used
to assess the association between invasion/ELISA/SPR.
P-values were considered significant if they were <0.05.
For collectively comparing the different recombinant pro-
teins, Annova by Kruskal-Wallis was used.
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Additional file
Additional file 1: Figure S1. Original SPR data where AMA1 was
bound to the chip (using N-terminal coupling). First plasma from one
individual living in PNG was injected over the chip, and antibodies from
plasma bound to AMA1. At around 200 seconds, buffer was flowed over
the chip to view the dissociation phase of the antibodies in plasma from
AMA1. At around 400 seconds, anti-IgG (Fig 1A) or anti-IgM (Figure 1B)
was injected until around 600 seconds, where buffer was again flowed
over the chip. For these data, it was not possible to calculate a kd value,
as we could not be sure whether the dissociation was due to only Ig, or
both anti-Ig and Ig coming off the chip. But from looking at the graphs
in the example shown, we can see a clear binding of anti-IgG but no
binding of anti-IgM. Figure S2. Original SPR data showing binding of
antibodies in plasma from an individual living in PNG, binding to N-terminally
coupled AMA1 (top curve), MSP2-3D7 (middle curve), MSP2-FC27 (bottom
curve). Plasma was flowed over the chip for 3 minutes (association phase)
and dissociation was measured for 10 minutes. Figure S3. Original SPR data
showing the monoclonal antibodies 6D8 (top curve), 9H4 (middle curve)
and 11E1 (bottom curve) binding to MSP2-FC27 (N-terminally coupled to
the chip). 11E1 is specific for MSP2-3D7 and does not bind to MSP2-FC27.
The antibodies were flowed over the chip for 3 minutes (association phase)
and dissociation was measured for 10 minutes.
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